Chen Cheng-Che, Yen Tsung-Han, Li Jian-Ri, Chen Chih-Jung, Yang Chi-Shun, Lai Jing-Yi, Lin Shu-Jiuan, Yeh Cheng-Hung, Hsu Shih-Wen, Lin Ming-Yu, Liu Tien-Jen, Chen Chuan Shu
Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan.
BioAnalytical Chemistry and Nanobiomedicine Laboratory, Department of Biochemical Science and Technology, National Taiwan University, Taipei, Taiwan.
Int Urol Nephrol. 2025 Mar;57(3):801-808. doi: 10.1007/s11255-024-04270-8. Epub 2024 Nov 7.
In Taiwan, the incidence of urothelial carcinoma of the upper urinary tract (UTUC) is high and intravesical recurrence is approximately 22%-47%. Thus, postoperative cystoscopy and urine cytology follow-up, which require experienced cytologists, are needed. The AIxURO system aligns with The Paris System (TPS) guidelines for reporting urinary cytology. This study assessed the benefit of early detection of intravesical recurrence after nephroureterectomy using the AIxURO system.
Urine cytology slides (n = 296) from 113 patients with UTUC were retrieved and patient data, pre-operative and postoperative cytology, pathology, and follow-up series for the intravesical recurrence group were collected. Cytology slides were digitized and independently assessed by the AIxURO system, and the results were compared to cytology reports.
From January 2022 to August 2023, 113 patients with UTUC underwent nephroureterectomy. Eighty-eight patients (88/113, 77.8%) received 1 or 2 cytology examinations pre-operatively, 44 slides (44/204, 21.5%) were positive and 34 patients (34/113, 30.1%) were diagnosed with UTUC. Postoperative intravesical recurrence was detected in 27 patients (27/113, 23%) at an average of 190.62 days. Thirty-four slides (34/56, 60.7%) were negative for UTUC. Eight patients (8/27, 29.6%) met the criteria for early diagnosis of intravesical recurrence. The AIxURO system identified two more patients (10/27, 37.0%) with early intravesical recurrence.
The AIxURO system enhanced postoperative urine cytology reporting confidence and could identify some underdiagnosed slides to enhance the early detection of UTUC with intravesical recurrence. AIxURO may be used for post-nephroureterectomy follow-up and reduce the necessity for cystoscopy.
在台湾,上尿路尿路上皮癌(UTUC)的发病率较高,膀胱内复发率约为22%-47%。因此,术后膀胱镜检查和尿液细胞学随访是必要的,而这需要经验丰富的细胞病理学家。AIxURO系统符合《巴黎系统》(TPS)关于尿液细胞学报告的指南。本研究评估了使用AIxURO系统早期检测肾输尿管切除术后膀胱内复发的益处。
检索了113例UTUC患者的尿液细胞学玻片(n = 296),收集了患者数据、术前和术后细胞学检查结果、病理情况以及膀胱内复发组的随访系列资料。将细胞学玻片数字化,并由AIxURO系统进行独立评估,然后将结果与细胞学报告进行比较。
2022年1月至2023年8月,113例UTUC患者接受了肾输尿管切除术。88例患者(88/113,77.8%)术前接受了1次或2次细胞学检查,44张玻片(44/204,21.5%)呈阳性,34例患者(34/113,30.1%)被诊断为UTUC。术后27例患者(27/113,23%)检测到膀胱内复发,平均时间为190.62天。34张玻片(34/56,60.7%)UTUC检测为阴性。8例患者(8/27,29.6%)符合膀胱内复发早期诊断标准。AIxURO系统又识别出另外2例(10/27,37.0%)膀胱内早期复发患者。
AIxURO系统增强了术后尿液细胞学报告的可信度,能够识别一些诊断不足的玻片,以提高对伴有膀胱内复发的UTUC的早期检测。AIxURO可用于肾输尿管切除术后的随访,并减少膀胱镜检查的必要性。